title: Preliminary results of liver transplantation for hepatocellular carcinoma among allocation organ policy strategies, neoadjuvant treatments, and intention-to-treat analysis.
abstract: We retrospectively evaluated the impact of our strategy for patients with hepatocellular carcinoma (HCC) according to an intention-to-treat analysis and drop-out probability. We evaluated only patients within the Milan criteria. We analyzed the outcomes of neoadjuvant strategies for HCC, organ allocation policy, and systematic application of strategies to increase the deceased donor pool as the current tendency to expand transplantability criteria for those patients. Kaplan-Meier survival probability rates at 1, 3, and 5 years according to an intention-to-treat analysis were 87.02%, 74.53%, and 65.93% for transplanted patients (n=108), and 50%, 14.29%, and 14.29% for the excluded or waiting list group (n=13), respectively (P< .0001). Drop-out risk at 3, 6, and 12 months was 2.40%, 8.59%, and 16.54%, respectively. During the same period, the mortality probability rates at 3, 6, and 12 months among patients without HCC awaiting orthotopic liver transplantation (OLT) were 3.60%, 9.50%, and 18.34%, respectively. Drop-out rate was lower among patients treated before OLT (P< .0001). On the basis of the neoadjuvant treatment results to reduce drop-out risk, we suggest avoiding the high priority for the HCC cohort, particularly within the first 6 months from entrance on the waiting list, because this approach can reduce the chances of patients with end-stage liver disease (ESLD) alone.
authors.affiliation: Department of General Surgery and Organ Transplantation, S. Martino Hospital, Genoa, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Andorno
authors.forename: G
authors.initials: G
authors.lastname: Bottino
authors.forename: N
authors.initials: N
authors.lastname: Morelli
authors.forename: M
authors.initials: M
authors.lastname: Casaccia
authors.forename: M
authors.initials: M
authors.lastname: Gelli
authors.forename: D
authors.initials: D
authors.lastname: Piredda
authors.forename: G
authors.initials: G
authors.lastname: Immordino
authors.forename: R
authors.initials: R
authors.lastname: Ferrante
authors.forename: I
authors.initials: I
authors.lastname: Nardi
authors.forename: B M
authors.initials: BM
authors.lastname: Troilo
authors.forename: S
authors.initials: S
authors.lastname: Di Domenico
authors.forename: F
authors.initials: F
authors.lastname: Ravazzoni
authors.forename: U
authors.initials: U
authors.lastname: Valente
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D016461:Chemoembolization, Therapeutic; D006291:Health Policy; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D016031:Liver Transplantation / Q000401:mortality / Q000706:statistics & numerical data*; D009362:Neoplasm Metastasis; D018579:Patient Selection; D040841:Resource Allocation; D012189:Retrospective Studies; D016019:Survival Analysis; D014850:Waiting Lists